Search results for: 'antibody drug market'

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

The research service aims to analyse and assess the global generics pharmaceutical market, map the key trends and dynamics shaping the industry sector and provide strategic recommendations for the success of the market participants. With several key blockbuster drugs losing patent protection and new healthcare reforms being introduced by the Govern...

Healthcare, as an industry, is entering a phase of rapid transformation. Digitization of products, services, and commerce models is democratizing current healthcare systems and unlocking new previously inaccessible segments. The fundamental convergence of healthcare with IT and retail industry continues to shift eCommerce from simple search portals...

Non-Alcoholic Steatohepatitis or NASH is a liver disorder that is characterized by the build-up of fat in liver in addition to inflammation and liver cell damage eventually progressing to cirrhosis. Currently lifestyle interventions are suggested for the treatment of NASH with no drugs having been approved for the condition. Multiple drugs are at ...

Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

23 Aug 2022  |  North America  |  Market Research

Global Bioanalytical Testing Services, 2021–2027

Acquisition of Disruptive Technologies will be the Key to Driving Growth

Infographics

×

Key Issues Addressed

As the pharma market recovers from the debilitating impact of COVID-19 on the drug discovery and development pipelines, there is an increasing requirement for outsourcing services in the form of contract research organizations (CROs) and contract development & manufacturing organizations (CDMOs), which is likely to drive the already strong drug dev...

The application of Generative AI (Gen AI) in healthcare is a rapidly growing field. In recent years, emerging applications in drug discovery and development, medical imaging analysis, digital twins, synthetic data, and electronic health records management, and virtual assistants have garnered significant interest thanks to their potential to revolu...

This strategic insight provides a comprehensive overview of the evolving US mobile device trade-in and protection market, with a focus on critical trends in reverse logistics and the underlying economics of trade-in programs. As the market matures, trade-in initiatives are increasingly recognized not only for driving customer acquisition and return...